Media

Nocturia... It's Not Overactive Bladder - Scott MacDiarmid

Details
(Length of Discussion: 20 min) Scott MacDiarmid presents on nocturia, the assessment, diagnosis, management and rationale for therapeutic treatment options. Nocturia is highly prevalent, and significantly impacts quality of life, so defining an algorithm for treatment is critical for the success in diagnosing early and treating effectively. Biography: Scott A. MacDiarmid, MD is director of the All...

Overview of Catheter Associated Urinary Tract Infections and Prevention Strategies - Shannon Novosad

Details
Diane Newman interviews Shannon Novosad from the Centers for Disease Control and Prevention, as she highlights details from her presentation on prevention of catheter-associated urinary tract infections (CAUTIs). Biographies: Shannon Novosad, MD, MPH, Medical Officer, Hospital Infection Prevention Team, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious...

Evolution of the NCCN Guidelines for Kidney Cancer -Tian Zhang

Details
(Length of Discussion: 12 min) Tian Zhang and Charles Ryan highlight recent updates in the NCCN treatment guidelines for kidney cancer resulting from data leading to changes in treatment options. Incorporation of initial diagnosis, disease biology, risk category, and clinical factors assist with selecting the most appropriate therapy for these patients. Biographies: Tian Zhang, MD, Assistant Profe...

The Prostate Cancer Foundation: a Discussion with Andrea Miyahira

Details
(Length of Discussion: 7 min) Andrea Miyahira and Alicia Morgans discuss the Prostate Cancer Foundation, the largest non-profit organization in the world, focused solely on funding for prostate cancer research and committed to advancing treatments for very late stage patients. Biographies: Andrea K. Miyahira, Ph.D., Dr. Andrea Miyahira has a Ph.D. in cancer immunology and is Director of Research a...

The Process of Metastasis in Prostate Cancer - Kenneth Pienta

Details
(Length of Discussion: 16 min) Charles Ryan and Ken Pienta discuss the process of metastasis in prostate cancer, referring to the seed and soil hypothesis and the influence of the tumor microenvironment and immune system. Biography: Kenneth J. Pienta, MD, The Donald S. Coffey Professor of Urology, Professor of Oncology, Professor of Pharmacology and Molecular Sciences, The Johns Hopkins Hospital R...

Laser Focal Therapy in Prostate Cancer - John Feller

Details
(Length of Interview: 20 min) John Feller is interviewed by John Fortin on laser focal therapy and focal laser ablation (FLA) therapy for the treatment in prostate cancer. He fields questions including his opinion on the typical candidate, availability and measuring side effects in FLA therapy. In addition, future plans to expand the scope in terms of the number of sites offering this therapy and...

Minimally Invasive Approaches in the Treatment of BPH: Ready to Replace TURP? - Claus Roehrborn

Details
Claus Roehrborn provides a state of the art review on contemporary management of male lower urinary tract symptoms and BPH. Biography: Claus Roehrborn, MD is at the Harold C. Simmons Comprehensive Cancer Center. Dr. Roehrborn is the S.T. Harris Family Chair in Medical Science, in Honor of John D. McConnell, M.D. and the E.E. Fogelson and Greer Garson Fogelson Distinguished Chair in Urology. A worl...

Immuno-Oncology in Bladder Cancer: The Urologist's Role - Noah Hahn

Details
In this lecture, Noah Hahn presents the importance of immuno-oncology (IO) - checkpoint inhibitors. Patients with urothelial carcinoma are receiving approved immuno-oncologic drugs that significantly extend survival and are safer and more tolerable than chemotherapy. The efficacy of immuno-oncologic agents in advanced urothelial cancer has naturally raised questions about their potential use in ea...

Genetic Evaluation of Hereditary Prostate Cancer - Sanjeev Kaul

Details
(Length of Presentation: 27 min) Sanjeev Kaul discusses hereditary prostate cancer (HPC) and why HPC is important, which patients should be tested based on the NCCN guidelines and what tests are available. Also, presented is the process for clinic testing for HPC and the future directions in this field. Biography: Sanjeev Kaul, MD, M.CH, Comprehensive Urology, Associate Professor of Urology, Oakla...

Is There an Optimal TURBT Technique and the Color War? - Ashish Kamat

Details
Ashish Kamat discusses the importance of TURBT and its value for diagnosis, therapeutic and prognostic purposes as an essential part of multidisciplinary care with specific regards to clinical trials. Ashish also compares different agents for the detection of bladder cancer and how these agents are reflected in the AUA/SUO Guidelines. Biography: Ashish Kamat, MD, MBBS , President, International Bl...